Comparative Pharmacology
Head-to-head clinical analysis: MELLARIL versus PROLIXIN ENANTHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELLARIL versus PROLIXIN ENANTHATE.
MELLARIL vs PROLIXIN ENANTHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors, and also blocks alpha-adrenergic receptors, histamine H1 receptors, and muscarinic M1 receptors.
Fluphenazine (the active entity of PROLIXIN ENANTHATE) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic and mesocortical pathways. It also exhibits alpha-adrenergic blocking and anticholinergic effects.
Typical adult dose: 10-25 mg orally 3 times daily. Maximum dose: 200 mg/day.
12.5-50 mg intramuscularly every 1-3 weeks. Initial dose: 2.5-12.5 mg IM as a test dose; gradual titration based on response and tolerability.
None Documented
None Documented
Terminal elimination half-life 21-24 hours; steady-state achieved within 5-7 days
Terminal elimination half-life approximately 11-15 days due to slow release from intramuscular depot; requires monitoring for prolonged effects after discontinuation
Primarily renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Primarily renal (30-40% as metabolites, <1% unchanged) and biliary/fecal (15-20%)
Category C
Category C
Antipsychotic
Antipsychotic